Detalhe da pesquisa
1.
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
Blood
; 120(22): 4324-33, 2012 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23033266
2.
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
Blood
; 118(19): 5126-9, 2011 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21856867
3.
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
Blood
; 117(24): 6450-8, 2011 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21498674
4.
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
Int J Cancer
; 131(11): 2693-703, 2012 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22488249
5.
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
Blood
; 115(18): 3796-800, 2010 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-20203261
6.
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
Blood
; 116(22): 4591-9, 2010 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-20651072
7.
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
J Cell Mol Med
; 15(10): 2057-70, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21091633
8.
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
Am J Hematol
; 85(9): 670-4, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20652865
9.
Targeting PIM kinase activity significantly augments the efficacy of cytarabine.
Br J Haematol
; 156(1): 129-32, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21689092
10.
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.
Leuk Lymphoma
; 47(11): 2339-43, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17107907
11.
Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
J Clin Oncol
; 22(14): 2800-7, 2004 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15254047
12.
Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
Cancer Gene Ther
; 10(11): 850-8, 2003 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-14605671
13.
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
J Clin Oncol
; 30(6): 631-6, 2012 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22271479
14.
A comparison of races and leukemia subtypes among patients in different cancer survivorship phases.
Clin Lymphoma Myeloma Leuk
; 11 Suppl 1: S114-8, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22035740
15.
Mammalian target of rapamycin as a target in hematological malignancies.
Target Oncol
; 6(1): 53-61, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21499765
16.
Targeting aurora kinases in cancer treatment.
Curr Drug Targets
; 12(14): 2067-78, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21777198
17.
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Cancer
; 117(10): 2127-35, 2011 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21523725
18.
A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy.
J Clin Pathol
; 64(9): 809-13, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21606230
19.
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
J Clin Oncol
; 28(8): 1422-8, 2010 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20142586
20.
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.
Drug Des Devel Ther
; 3: 89-101, 2009 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19920925